Cargando…
Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras
Breast cancer is the most common cancer in women worldwide. Despite recent developments in breast cancer detection and treatment, 1.38 million women each year are still affected. Breast cancer heterogeneity at the population and single-cell level, complexity and developing different metastases are s...
Autores principales: | Nachreiner, Inga, Hussain, Ahmad Fawzi, Wullner, Ulrich, Machuy, Nikolaus, Meyer, Thomas F., Fischer, Rainer, Gattenlöhner, Stefan, Meinhold-Heerlein, Ivo, Barth, Stefan, Tur, Mehmet Kemal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755278/ https://www.ncbi.nlm.nih.gov/pubmed/31555351 http://dx.doi.org/10.3892/etm.2019.7753 |
Ejemplares similares
-
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
por: Maennling, Amaia Eleonora, et al.
Publicado: (2019) -
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
por: Kruspe, Sven, et al.
Publicado: (2017) -
A Universal Protein Tag for Delivery of SiRNA-Aptamer Chimeras
por: Liu, Hong Yan, et al.
Publicado: (2013) -
Synergistic Targeting HER2 and EGFR with Bivalent
Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018) -
EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer
por: Subramanian, Nithya, et al.
Publicado: (2015)